Pfizer’s Nasal Spray for Migraines Set to Hit Pharmacies

 Pharmaceutical giant Pfizer has announced that its new nasal spray treatment for migraines is soon to be available in pharmacies.

Pfizer’s Nasal Spray for Migraines Set to Hit Pharmacies

Pfizer's Zavzpret: A New Nasal Spray Treatment for Migraines

Pfizer has recently announced the development of a new nasal spray treatment for migraines called Zavzpret. This medication has been approved by the FDA for use in adults and offers an alternative approach to migraine treatment for those who cannot tolerate oral medication.

What is Zavzpret and How Does it Work?

Zavzpret is a nasal spray medication for migraines that works by blocking calcitonin gene-related peptides (CGRP), a type of protein that is present in higher levels during migraine attacks and has been linked to pain and inflammation. Unlike triptans, which work by constricting blood vessels, Zavzpret works by targeting CGRP receptors in the brain. By blocking CGRP, Zavzpret can provide relief from migraine symptoms, including pain and sensitivity to light and sound.

Pfizer's Acquisition of Biohaven and Zavegepant

In May 2022, Pfizer acquired Biohaven, a pharmaceutical company that was developing a nasal spray for migraines called "zavegepant." This acquisition allowed Pfizer to add a promising new medication to its portfolio for the treatment of migraines, a condition that affects millions of people worldwide.

Zavegepant: A New Approach to Migraine Treatment

Zavegepant is a nasal spray medication for migraines that works by blocking CGRP. Unlike existing migraine treatments, zavegepant works by blocking CGRP instead of constricting blood vessels with triptans. This new approach provides an alternative for people who cannot tolerate oral medications and has the potential to improve the lives of those who suffer from migraines.

Phase 3 Trial Results and FDA Approval

In a phase 3 clinical trial involving about 1,400 people, zavegepant showed promising results for the treatment of migraines. The trial found that 24% of participants who used the nasal spray were free from pain within two hours, compared to 15% in the placebo group. These promising results led to the FDA's approval of Pfizer's nasal spray for migraines for use in adults, making it the first CGRP inhibitor delivered via nasal spray. The FDA's approval of zavegepant provides new hope for the millions of people worldwide who suffer from migraines.